Travere Therapeutics (TVTX) Common Equity (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Common Equity came in at $98.7 million in Q1 2026, up 200.79% YoY from $32.8 million in Q1 2025, and down 14.02% on a QoQ basis from $114.8 million in Q4 2025.
Travere Therapeutics (TVTX) Common Equity (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Common Equity data on file, last reported at $98.7 million in Q1 2026.
- Quarterly Common Equity rose 200.79% year-over-year to $98.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.7 million (up 200.79% YoY) and the FY2025 annual result came in at $114.8 million, up 94.37% from the prior year.
- Common Equity retreated to $98.7 million in Q1 2026, from $114.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $279.8 million in Q3 2023 to a low of -$30.5 million in Q3 2024.
- A 5-year average of $103.8 million and a median of $98.7 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity jumped 368.62% — and 2024, when it sank 110.89%.
- Tracing TVTX's Common Equity over 5 years: stood at $42.9 million in 2022, then surged by 368.62% to $200.8 million in 2023, then slumped by 70.58% to $59.1 million in 2024, then surged by 94.37% to $114.8 million in 2025, then declined by 14.02% to $98.7 million in 2026.
- The last three Common Equity figures came in at $98.7 million (Q1 2026), $114.8 million (Q4 2025), and $73.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 24.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.52 Mn |
| Mar 31, 2026 | 98.73 Mn |
| Dec 31, 2025 | 114.83 Mn |
| Sep 30, 2025 | 73.56 Mn |
| Jun 30, 2025 | 32.75 Mn |
| Mar 31, 2025 | 32.82 Mn |
| Dec 31, 2024 | 59.08 Mn |
| Sep 30, 2024 | -30.45 Mn |
| Jun 30, 2024 | 15.15 Mn |
| Mar 31, 2024 | 74.07 Mn |
| Dec 31, 2023 | 200.81 Mn |
| Sep 30, 2023 | 279.77 Mn |
| Jun 30, 2023 | 116.49 Mn |
| Mar 31, 2023 | 189.14 Mn |
| Dec 31, 2022 | 42.85 Mn |
| Sep 30, 2022 | 100.68 Mn |
| Jun 30, 2022 | 156.71 Mn |
| Mar 31, 2022 | 208.14 Mn |
| Dec 31, 2021 | 302.11 Mn |
| Sep 30, 2021 | 307.37 Mn |